Alfasigma S.p.A. has agreed to acquire 100% of Nordic Group B.V., the specialty pharmaceutical business operating as Nordic Pharma, from SEVER Life Sciences B.V. in a transaction that will substantially expand Alfasigma’s European rheumatology portfolio and international commercial infrastructure. Announced on August 11, 2026, the proposed acquisition brings approximately €190 million of 2025 revenue, 265 employees and direct operations across 18 European countries, alongside commercial platforms in Canada and Japan. Financial terms were not disclosed.
The most strategically important asset is Nordic Pharma’s established rheumatoid arthritis franchise led by Nordimet, an injectable methotrexate product available in pre-filled syringe and auto-injector presentations. Alfasigma already owns the Jyseleca filgotinib business in Europe and the United Kingdom, giving the combined company exposure to different stages of rheumatoid arthritis treatment rather than simply adding another geographically adjacent pharmaceutical brand.
Nordic Pharma also contributes women’s health, critical care and ophthalmology products, making the transaction broader than the rheumatology rationale highlighted by Alfasigma. Its ophthalmology platform has recently expanded through the European introduction of Lacrifill Canalicular Gel, while the wider portfolio includes products such as the Mifegyne mifepristone franchise in women’s health. Product availability and indications vary by country, an important qualification for assessing the revenue and cross-selling opportunities within such a geographically fragmented portfolio.
For Alfasigma, the transaction arrives during a period of unusually active portfolio construction. The privately owned Italian pharmaceutical company generated approximately €1.8 billion in 2025 revenue and has been redirecting resources toward gastroenterology, immunology, specialty care and rare diseases through acquisitions and licensing transactions. Nordic Pharma’s €190 million revenue base is therefore equivalent to roughly 10.6% of Alfasigma’s reported 2025 revenue, although that comparison is not a pro forma forecast and does not account for transaction timing, accounting adjustments or portfolio changes.
Why does the Nordic Pharma acquisition matter for Alfasigma’s European rheumatology strategy?
The clearest strategic logic sits in rheumatology. Nordic Pharma’s Nordimet franchise is based on methotrexate, a long-established immunomodulatory therapy used across inflammatory disease management, while Alfasigma’s existing Jyseleca franchise gives the company a differentiated specialty medicine platform in rheumatoid arthritis and ulcerative colitis. Jyseleca is marketed by Alfasigma in European Union and European Economic Area countries and the United Kingdom for its approved indications.
The combination potentially gives Alfasigma a wider commercial relationship with rheumatology specialists rather than a simple product-volume expansion. Nordimet and Jyseleca occupy distinct positions within inflammatory disease treatment, meaning the transaction adds commercial breadth without implying that the products are interchangeable or intended for the same patients.
That distinction matters. The value of the transaction does not depend on demonstrating clinical synergy between methotrexate and filgotinib. The more defensible strategic case lies in commercial infrastructure, relationships with rheumatologists, medical-affairs capabilities and the ability to support multiple products across overlapping specialist channels.
Alfasigma has already demonstrated that rheumatology is becoming a larger part of its portfolio. The company completed its acquisition of the Jyseleca business from Galapagos in January 2024, incorporating marketing authorisations, commercial operations, medical affairs and development activities across Europe and bringing approximately 400 employees from Galapagos into the organisation.
Nordic Pharma therefore represents another layer of scale rather than Alfasigma’s first move into the field.
How significant is Nordic Pharma’s €190 million revenue contribution to Alfasigma?
Nordic Pharma generated approximately €190 million of revenue in 2025, according to Alfasigma. Against Alfasigma’s €1.8 billion of reported 2025 revenue, the acquired business represents a revenue base equivalent to around 10.6% of the buyer’s existing annual sales.
That percentage helps explain why the transaction should not be viewed merely as the purchase of Nordimet. Alfasigma is acquiring an operating specialty-pharmaceutical organisation with established revenues, personnel and country-level infrastructure.
The comparison is particularly relevant because Alfasigma’s reported 2025 revenue declined 4% year on year to €1.8 billion, partly reflecting the voluntary withdrawal of Ocaliva from the United States market. On a like-for-like basis excluding that impact, the company reported 7% revenue growth, while immunology revenue increased 17%, gastroenterology 15% and vascular health 10%.
That backdrop makes the Nordic Pharma transaction consistent with a broader attempt to increase the weight of specialty businesses that Alfasigma considers strategic.
The acquired workforce is meaningful as well. Alfasigma says it employs approximately 4,000 people, while Nordic Pharma will add 265 employees through the transaction, equivalent to roughly another 6.6% of Alfasigma’s current workforce before integration adjustments.
For a pharmaceutical acquisition, those employees may be as strategically relevant as the product rights. Established specialty-care businesses depend on regulatory knowledge, local market access, medical affairs, distribution relationships and physician engagement that cannot always be replicated simply by purchasing a drug licence.
Why are Nordic Pharma’s European operations as important as its pharmaceutical products?
Nordic Pharma has developed a comparatively broad footprint for a medium-sized specialty pharmaceutical company. Its existing organisation spans numerous European markets, while Alfasigma says the acquisition will leave the combined organisation with Nordic Pharma direct operations across 18 European countries and will add commercial platforms in Canada and Japan.
That infrastructure offers Alfasigma something pharmaceutical companies increasingly seek through acquisitions: ready-made commercial reach.
Building a direct specialist pharmaceutical organisation country by country requires regulatory resources, medical affairs teams, local reimbursement expertise and sales infrastructure. Acquiring an established company can compress that expansion process, although successful integration remains dependent on retaining employees and preserving relationships with clinicians, distributors and healthcare systems.
The transaction also follows Alfasigma’s earlier integration of Jyseleca operations across Europe. In that acquisition, approximately 400 Galapagos employees across 14 European countries were expected to move to Alfasigma, creating a specialty commercial platform that the Nordic Pharma business could now deepen.
There is nevertheless an important geographic boundary around the new transaction. While Nordic Pharma currently describes a wider global footprint that includes a United States affiliate, SEVER Life Sciences said that after completion it will continue to own Nordic Pharma Inc. alongside its other retained businesses. Alfasigma’s own transaction announcement specifically identifies Europe, Canada and Japan as the geographic additions and does not describe the United States business as part of the acquired platform.
That means the deal should not be interpreted as giving Alfasigma Nordic Pharma’s entire existing global structure.
What other products could broaden Alfasigma beyond rheumatology?
Although rheumatology provides the most obvious strategic overlap, Nordic Pharma also operates in women’s health, critical care and ophthalmology. Its portfolio combines proprietary and in-licensed products, which means the economics, geographic rights and lifecycle opportunities are likely to vary considerably between individual assets.
Ophthalmology could become particularly interesting because Nordic Pharma has been investing in Lacrifill Canalicular Gel. The company launched Lacrifill in European markets in February 2026 following CE marking in 2025. The cross-linked hyaluronic acid gel is intended to temporarily occlude the canalicular system and reduce tear drainage in dry-eye management.
That does not automatically make ophthalmology a new core therapeutic area for Alfasigma. A product launch, even one supported by regulatory conformity and an established commercial organisation, still requires physician uptake, appropriate patient selection and effective country-by-country commercial execution.
The broader relevance is portfolio optionality. Alfasigma is acquiring a company whose revenue is not dependent on one rheumatoid arthritis franchise, potentially giving management several platforms from which to evaluate future licensing, product acquisition or geographic expansion opportunities.
Women’s health is another established component of Nordic Pharma’s business, including medicines such as Mifegyne and misoprostol products. As Nordic Pharma itself cautions, not every product or indication is licensed in every country, so the commercial footprint cannot be assumed to be uniform across the acquired markets.
How does the Nordic Pharma deal fit Alfasigma’s increasingly aggressive specialty-pharma expansion?
The acquisition is the latest step in a sequence of transactions that has progressively moved Alfasigma toward specialty and rare diseases.
The Jyseleca acquisition in 2024 provided an established immunology franchise and European specialist organisation. More recently, Alfasigma secured worldwide exclusive rights from GSK plc to develop, manufacture and commercialise linerixibat, now marketed in the United States as Lynavoy following United States Food and Drug Administration approval for cholestatic pruritus associated with primary biliary cholangitis in adults.
The linerixibat transaction alone illustrates the financial scale of Alfasigma’s strategy. GSK received $300 million upfront and another $100 million following United States approval, with additional regulatory and sales-based milestone payments potentially bringing the consideration to $690 million before royalties.
Nordic Pharma is structurally different because Alfasigma is acquiring a functioning company with existing revenues, staff, marketed products and commercial infrastructure rather than licensing a single pharmaceutical asset.
Together, however, the transactions point in the same direction. Alfasigma is moving beyond its historical strength in established gastroenterology and primary-care products toward a model containing more specialist medicines, rare-disease assets and dedicated commercial capabilities.
What still has to happen before Alfasigma owns Nordic Pharma?
The deal has been signed but has not yet completed. It remains subject to customary closing conditions, including regulatory approvals where required, and SEVER Life Sciences expects completion by the end of the fourth quarter of 2026. Until closing, the companies are continuing to operate independently.
The lack of disclosed financial terms also leaves a major analytical gap. Investors and industry observers cannot assess the acquisition multiple paid against Nordic Pharma’s approximately €190 million revenue or determine how much value Alfasigma has assigned to Nordimet, the broader product portfolio and the acquired commercial infrastructure.
Integration will become the next measurable test once regulatory conditions are satisfied. Alfasigma is not simply absorbing pharmaceutical rights. It will need to integrate 265 employees, multiple therapeutic areas and operations across a substantial number of markets while maintaining product supply, regulatory responsibilities and existing relationships with healthcare professionals.
If that integration is executed effectively, Nordic Pharma could give Alfasigma something difficult to build organically: an immediately revenue-producing specialty pharmaceutical platform whose size is equivalent to more than one-tenth of Alfasigma’s 2025 revenue base, combined with deeper European rheumatology coverage and new commercial positions in Canada and Japan. The strategic rationale is therefore broader than Nordimet alone. The bigger question is whether Alfasigma can turn its rapidly expanding collection of acquired products and commercial organisations into a coherent specialty-care business rather than simply a larger portfolio of assets.